Evidence map›Paper›PMID 33224417›Full record

ArticleThe Pan African medical journal2020

Assessment of eligibility for thrombolysis in acute ischaemic stroke patients in Morocco.

Mohamed Acherqui, Hajar Khattab, Younes Habtany, Rim Amzil, Salma Bellakhdar, Hicham El Otmani, Bouchra El Moutawakil, Mohammed Abdoh Rafai

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Global stroke statistics 2023: Availability of reperfusion services around the world.International journal of stroke : official journal of the International Stroke Society · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohamed AcherquiNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Hajar KhattabNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Younes HabtanyNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Rim AmzilNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Salma BellakhdarNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Hicham El OtmaniNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Bouchra El MoutawakilNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Mohammed Abdoh RafaiNeurological Department, IBN ROCHD University Hospital, Casablanca, Morocco.
Centre Hospitalier Universitaire Ibn Rochd · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionintravenous thrombolysis with recombinant tissue plasminogen activator (rTPA) is an approved treatment for acute ischaemic stroke (AIS). However, its use remains low. We aimed to assess the eligibility of thrombolysis for our patients with AIS before implementing this treatment method in our teaching hospital.

methodswe conducted a prospective cross-sectional study in the emergency department of Casablanca University Hospital. We included every patient admitted for a stroke-related symptom. Delays between symptom-onset and admission and delays regarding the in-hospital evaluation of patients were recorded. Patients eligible for intravenous thrombolytic therapy were identified according to American Heart Association guidelines.

resultsin all, 463 patients were included. Only 8.42% of patients were eligible for thrombolysis; 74% of patients were ineligible because of an onset-to-thrombolysis delay longer than 4.5 hours. Mean onset-to-thrombolysis time was 27.2 hours. Patients were admitted with a mean delay of 24.9 hours. The in-hospital evaluation, from admission to computerized tomography (CT) interpretation, averaged 2.3 hours in length.

conclusionthe percentage of patients eligible for thrombolysis remains very low in our structure. The majority would not have benefitted from the therapy because of an extra hospital delay far exceeding the recommended therapeutic window. To shorten our delays and increase the number of patients benefiting from thrombolysis, we must implement strategies aiming to improve the recognition, evaluation and management of patients from the general public to the neurovascular unit.

Indexed as

Administration, IntravenousAdolescentAdultAgedAged, 80 and overCross-Sectional StudiesEmergency Service, HospitalFemaleFibrinolytic AgentsHumansIschemic StrokeMaleMiddle AgedMoroccoProspective StudiesThrombolytic TherapyFibrinolytic AgentsTissue Plasminogen ActivatorEligibility

Identifiers

PMID33224417
PMCPMC7664138
OpenAlexW3081038914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.